2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5072 Lower intensity bridging with inotuzumab ozogamicin or mini-CVD plus venetoclax prior to chimeric antigen receptor T-cell therapy in B-cell precursor acute lymphoblastic leukemia

Jose Tinajero, PharmD, Kim Nguyen, PharmD2, Tamer Othman, MD3, Vaibhav Agrawal, MD4, Paul Koller, MD5, Dat Ngo, PharmD6, Lindsey A. Murphy, MD, MSCS7, Hoda Pourhassan, MD8, Yazeed Samara, MD9, Amandeep Salhotra, MD10, Stephen J. Forman, MD11, Anthony Selwyn Stein, MD12, Guido Marcucci, MD13, Vinod Pullarkat, MD14, Ibrahim Aldoss, MD15
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States

Background
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL). High pre-lymphodepletion (LD) disease burden correlates with increased CAR-related toxicities and inferior outcomes post CAR-T. As a result, bridging therapy (BT) is frequently utilized to maintain disease control and/or reduce disease burden pre-LD. Currently, there is no consensus regarding the optimal BT for patients (pts) with B-ALL, and comparative data evaluating different approaches remains limited. Here, we describe our experience between two lower intensity BT: mini-CVD combined with venetoclax (miniCVD-Ven) and inotuzumab ozogamicin with or without chemotherapy (Ino).


Methods
This retrospective analysis included adult pts aged 18 years or older who underwent BT with either miniCVD-Ven or Ino prior to CAR-T therapy. Demographics, clinical characteristics, regimen safety and efficacy, and post-CAR-T therapy outcomes—including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), response rate, and measurable residual disease (MRD) negativity were described. OS was estimated using the Kaplan–Meier method, and its associated 95% confidence interval (CI) (RStudio, version 3, Boston, MA). MRD negativity was defined as achieving <0.01% leukemic cells of total nucleated cells and was assessed by multiparameter flow cytometry.


Results
44 pts with B-ALL who underwent BT with either miniCVD-Ven (n=20) or Ino (n=24) prior to CAR-T therapy were included.  Baseline characteristics were largely comparable between the miniCVD-Ven and Ino groups. Most pts had active disease (95% vs 88%, p=.38), with baseline bone marrow blast (BMB) (51.5% vs 70%, p=0.2), Hispanic/Latino ethnicity (80% vs 83%, p=0.77), and median prior number of prior lines of therapy (2 vs 2, p=0.5). However, a significantly greater proportion of pts in the Ino group had ≥2 prior lines of therapy (65% vs. 92%, p=0.02). Pts in the InO cohort also tended to be older (median age, 36 vs. 27.3, p=0.05). Ph-like ALL was the most common disease subtype (45% vs 54%, p=0.54). In the InO cohort, half of the pts received inotuzumab in combination with cytotoxic chemotherapy.

 

Post BT, overall response rate (ORR) was 50% for miniCVD-Ven vs. 71% for Ino (p=0.15), with complete response/CR with incomplete count recovery (CR/CRi) rates of 40% vs. 58% (p=0.22). MRD negativity amongst responders was achieved in 25% (2/8) of evaluable pts in the miniCVD-Ven group compared to 86% (12/14) in the Ino group (p=0.004). Higher median (Range) percent BMB change from baseline was trending in the Ino cohort; -83.4% (-100 % to 500%) vs -100% (-100% to 4.2%), p=0.09. Both regimens demonstrated manageable toxicity profiles with low rates of Grade ≥3 non-hematologic toxicities (5% vs. 13%, p=0.34) and ICU admissions (5% vs. 4%). Febrile neutropenia occurred in 40% vs. 29% (p=0.45). No significant differences were noted in median time to ANC recovery (20 vs. 26 days, p=0.738) or platelet recovery (23 vs. 25 days, p=0.41) after BT.

Median time to CAR-T infusion from Day 1 of BT was 1.96 months for miniCVD-Ven and 2.0 months for Ino. Post-CAR-T, pts receiving miniCVD-Ven experienced higher rates of all grade CRS (90% vs. 54%, p<0.01) and Grade 3–4 CRS (5% vs. 0%, p<0.01). ICANS rates were not significantly across cohorts (Grade 3–4 ICANS: 5% vs. 21%, p=0.12). Post-CAR-T CR/CRi rates were high in both cohorts (79% vs. 96%, p=0.09) with high rates of post-CAR-T MRD negativity amongst responders (100% vs. 95%, p=0.4). A total of 55% of pts in the miniCVD-Ven group and 38% in the Ino group underwent post-CAR-T alloHCT (p=0.24). The median OS (mOS) was not reached (NR) (95% CI; 14.6 months – NR). There was no significant difference in mOS between miniCVD and Ino (p=0.9)

 


Conclusions
Both miniCVD-Ven and Ino serve as effective BT prior to CAR-T therapy in B-ALL, particularly in those with chemotherapy-refractory disease, achieved meaningful cytoreduction and enabled patients to safely proceed to CAR-T infusion, with many subsequently undergoing alloHCT. Both strategies yielded excellent post-CAR-T response rates and high rates of MRD negativity.

Jose Tinajero, PharmD: No relevant conflicts of interest to declare.